

REGISTER BY DECEMBER 15, 2017 AND SAVE \$300!



Specialty Therapies 2018

A Forum for Payers

Manage Cost, Expand Access, Improve Patient Services and Care Delivery

JANUARY 25-26, 2018 | MONTE CARLO | LAS VEGAS, NV

OUR 2018 EXPERT SPEAKING FACULTY INCLUDES:



CHAIRPERSON:

Katy Wong, R.Ph., MBA,
VP Producer Relations,
CIGNA



Francis J. Rienzo,
Vice President of Advocacy
and Government Relations,
**Medicaid Health Plans of
America (MHPA)**



Nick Page,
Vice President Specialty and
Clinical Operations,
US Specialty Care



Jeff Blake,
Senior Vice President,
Payer Relations,
Hemophilia Alliance









Kayse Reitmeyer,
Pharmaceutical Manufacturer
Relations Director,
Highmark Inc.



Doug Gebhard, Pharm.D., MBA,
Vice President Quality &
Education, **PANTHERx
Specialty Pharmacy**

THE HOTTEST ISSUES IN SPECIALTY THERAPY MANAGEMENT ARE ADDRESSED DURING IN-DEPTH DISCUSSIONS AND THOUGHT-PROVOKING SESSIONS:

-  **Rebate programs** — An examination of how rebates effect patients and payments
-  **Considerations when looking at rare and orphan disease treatments**
-  **Examine real world therapy management program response to PCSK9 medications**
-  **Adapt programs and value-based design strategies to manage the high costs of pharmaceuticals**
-  **Gain an analysis of the biosimilars pipeline and anticipate access barriers**
-  **A multi-stakeholder examination of value frameworks and its implementation for specialty therapies**



PLUS! PRE-CONFERENCE WORKSHOP
Considerations for Accreditation and Expanding Reach for Specialty Pharmacies

NEW! CASE STUDY ON
Highmark's Site of Care Program



Premier Media Partners:



Drug Topics

Supporting Media Partners:



**Pharmaceutical
Executive**



PharmVOICE



BioPharmaDIVE



**Pharmacy
Times**

REGISTER AT WWW.CBINET.COM/SPECIALTYTHERAPIES • 800-817-8601

"Specialty drugs accounted for more than one-third of total prescription drug spending in 2016, and by 2020 they are expected to represent almost 50% of drug sales."

— *Specialty Drug Costs to Soar Again in 2018*, **CFO**
September 22, 2017

WHAT THE INDUSTRY IS SAYING:

"I found the program to be **WELL-DESIGNED**
and stimulating, well worth my time."

— *Executive Director,*
MidAtlantic Business Group on Health

"CLASS ACT!"

— *Director of Specialty Pharmacy Programs,*
BlueCross BlueShield South Carolina

"The specialty pharmacy arena is constantly evolving.

QUALITY CONFERENCES like CBI's Specialty Therapies Forum for Payers allows payers and industry alike to hear from KOLs and prepare for the challenges that they are currently dealing with or will be facing in the near future."

— *Director, Clinical Pharmacy,*
BlueCross BlueShield of Tennessee

WHO SHOULD ATTEND:

You will benefit from attending this event if you work at a health plan, PBM, ACO or specialty pharmacy and have the following titles:

- Pharmacy Benefit Manager
- Chief Medical Officer/Medical Director
- Chief Pharmacy Officer
- Specialty Pharmacy Director/Manager
- Director of Pharmacy Services
- Pharmacy Vice President/Director/Manager

This conference will also benefit consultants, pharmaceutical, medical device and biotechnology companies, infusion centers, group purchasing organizations or technology providers.



DAY ONE

THURSDAY, JANUARY 25, 2018

7:30 Workshop Registration and Continental Breakfast

8:30 **WORKSHOP** | **Considerations for Accreditation and Expanding Reach for Specialty Pharmacies**

Workshop Objective:

Upon completion of this workshop, participants will:

- Understand the importance of accreditation as a specialty pharmacy and how it impacts specialty network access
- Be able to identify key operational elements that differ between traditional and specialty pharmacy
- Be able to identify various resources available to help patients afford specialty medications
- Understand key operational areas where greater support is required in specialty pharmacy
- Understand the clinical management that is expected in specialty pharmacy
- Understand the differences between adherence and persistence and the specialty pharmacists role in improving both
- Understand factors associated with specialty network access
- Understand DIR fees and how specialty pharmacies need to consider them in their financial planning

Key Questions to Be Addressed:

- How to better service your patient without digging into your bottom line
- How to become part of manufacturer LDNs
- How to ask manufacturer for support regarding patient education and adherence
- How are orphan drugs effecting the specialty pharmacy industry?

Workshop Outline:

- I. **Specialty Pharmacy Accreditation**
 - What is accreditation
 - Why is it required
 - Who are the organizations
- II. **Specialty Operations**
 - Prescription intake
 - Benefits investigation
 - Prior authorization process
 - Funding and financial assistance
 - Patient onboarding
- III. **Clinical Management**
 - Patient education plan/counseling
 - Initial assessment/care plan
 - Adherence/persistence
 - Requirements for specialty disease states (per accreditation and payers)
 - Building and executing disease management protocols
- IV. **Contracting and Network Participation**
 - Retail vs. specialty networks
 - Different requirements by payers
 - DIR fees (direct and indirect remuneration)
 - * what are they
 - * why do they exist
 - * how does it impact specialty pharmacy

Workshop Leaders:

Nick Page, Vice President Specialty and Clinical Operations,

US Specialty Care

Doug Gebhard, Pharm.D., MBA, Vice President Quality & Education,

PANTHERx Specialty Pharmacy

There will be a 30-minute networking and refreshment break at 10:00am

12:00 Close of Workshop



DAY ONE | MAIN CONFERENCE THURSDAY, JANUARY 25, 2018

12:00 *Registration and Refreshments*

1:15 *Chairperson's Welcome and Opening Remarks*
Katy Wong, RPh, MBA, Vice President Producer Relations, **CIGNA**

1:30 **Rebate Programs — An Examination of How Rebates Affect Patients and Payments**

- The creation of the program
- How the market place has changed now that alignments have changed
- New paradigm is needed
- Medicaid savings central of focus of repeal and replace

Francis J. Rienzo, Vice President of Advocacy and Government Relations, **Medicaid Health Plans of America (MHPA)**



PANEL

2:15 **Multi-Stakeholder Examination of Value Frameworks and Their Implementation for Specialty Therapies**

- Defining value — Costs & quality of life
- Different frameworks — Pros and cons
- Who ascribes value — Data, doctor, patient

MODERATOR:

Joseph Fuhr, Professor Economics,
Thomas Jefferson University

PANELISTS:

Kayse Reitmeyer, Pharmaceutical Manufacturer Relations Director,
Highmark Inc.

Peter Dehnel, Medical Director, **CentraCare HealthSystem**

Lyn Fitzgerald, Senior Vice President, U.S. and Global Development,
National Comprehensive Cancer Network (NCCN)

Jeff Blake, Senior Vice President Payor Relations,
Hemophilia Alliance

3:00 *Networking and Refreshment Break*



CASE STUDY

3:30 **Managing High Cost Complex Conditions — A Case Study**

- Enhanced cost management
- Care coordination to enhance quality and lower cost
- Enhancing prescription drug compliance to improve quality of care, lower cost and enhance quality of life

Jeff Blake, Senior Vice President Payor Relations,
Hemophilia Alliance

4:15 **Orphan Drugs — The Reinvention of Specialty Pharmacy?**

- Review the impact and status of legislation
- Delineate trends in FDA approvals & pipeline
- Discuss economic implications on healthcare
- Compare contemporary channel strategies

Doug Gebhard, Pharm.D., MBA, Vice President Quality and Education, **PANTHERx Specialty Pharmacy**

5:00 **How Can Payers and Manufacturer Work Together to Establish Appropriate Utilization Guidelines**

- Educating providers and patients on rare diseases and optimizing treatment — A win/win/win for all stakeholders
- Controlling patient on-boarding and dispensing to optimize treatment

Mark Irwin, Principle, **Square Hill Company**

5:45 *Close of Day One*



Networking, Wine and Cheese Reception
immediately following the final session on day one



DAY TWO FRIDAY, JANUARY 26, 2018

8:00 *Continental Breakfast*

8:30 *Chairperson's Review of Day One*
Katy Wong, RPh, MBA, Vice President Producer Relations, **CIGNA**

8:45 **Real World Therapy Management Program Response to PCSK9 Medications**

- Review PCSK9-inhibitors and their market impact in the last year
- Evaluate available prior authorization criteria
- Explore structure of hyperlipidemia therapy management program
- Examine real-world outcomes and evaluation of therapy management program

Daniel Jude, Pharm.D., AAHIVP, Manager Specialty Clinical Services,
Fairview Specialty Services Pharmacy



CASE STUDY

9:30 **Highmark's Site of Care Program**

Leah King, PharmD, JD, Manager,
Pharmacy Strategy, Highmark Inc.

10:15 *Networking and Refreshment Break*

10:45 **ACA Update and Its Impact on Specialty Therapies**

- Get an up-to-the-minute update on the efforts to overhaul the Affordable Care Act and what they could mean for you and your company
- Learn how open enrollment for 2018 went and what to expect from the year ahead
- Find out how changes for Marketplace health plan rules for 2019 could impact coverage of specialty therapies

*Melissa Andel, Health Policy Director, **Applied Policy***

11:30 **Examining Drug Distribution Channels for Specialty Therapies**

- PBM consolidation
- What are synergies in market place?
- Impact to pharmaceutical companies

*Carlos Alfaras, President and CEO, **Gensco Pharma***

12:15 **Networking Luncheon**

1:30 **Considerations When Looking At Rare and Orphan Disease Treatments**

- Physicians serving as patient advocates at a local, regional and national level
- Challenging conditions the insurance world is confronted with in terms of coverage
- Care management, care enhancements and adherence compliance — Why these are important for all sides
- Enhancing the likelihood of coverage at the highest level possible

*Peter Dehnel, Medical Director, **CentraCare HealthSystem***

2:15 **The Biosimilars Pipeline and Anticipated Access Barriers**

- Barriers to entry
- Cost of research and development
- Uncertainty of getting a drug past the FDA
- Litigation issues
- Response of reference product/competition

Joseph Fuhr, Professor Economics,

Thomas Jefferson University

3:00 **Chairperson's Closing Remarks**

*Katy Wong, RPh, MBA, Vice President Producer Relations, **CIGNA***

3:15 **Close of Conference**



REGISTER AND WE DONATE TO A GOOD CAUSE

Las Vegas has been the home to the Specialty Therapies Forum for more than a decade, and we look forward to many more years to come. In an effort to show support to this incredible community, CBI will donate a portion of each registration for the Specialty Therapies Forum to a charity associated with the recent tragic events Las Vegas has faced.

For more information, please email marketing@cbinet.com.

A GREAT PLACE TO MEET YOUR MARKET!

Maximize your access to decision-makers and align your brand with the life sciences industry's premier thought-leaders and industry innovators. CBI's custom sponsorship programs are designed to support your organization's overall business development and marketing initiatives through meaningful prospect and customer interactions, brand assertion campaigns and content-rich thought-leadership opportunities. Capitalize on the life sciences community's premier platform for peer-to-peer exchange, solution driven content and first-in-class networking opportunities. For more information on how to position your company as a sponsor or exhibitor, contact **Kelsey Maloney** at **339-298-2257** or email kelsey.maloney@cbinet.com.





Specialty Therapies 2018

A Forum for Payers

Manage Cost, Expand Access, Improve Patient Services and Care Delivery

JANUARY 25-26, 2018 | MONTE CARLO | LAS VEGAS, NV



SCAN HERE



4 WAYS TO REGISTER NOW!



WEB
[www.cbinet.com/
specialtytherapies](http://www.cbinet.com/specialtytherapies)



EMAIL
cbireg@cbinet.com



PHONE
800-817-8601
339-298-2100 outside the U.S.



LIVE CHAT
[www.cbinet.com/
specialtytherapies](http://www.cbinet.com/specialtytherapies)



CBI
70 Blanchard Road
Burlington, MA 01803

ANY QUESTIONS OR TO REGISTER CONTACT:

Juliet Nelson

PHONE 339-298-2140

EMAIL juliet.nelson@cbinet.com

Specialty Therapies 2018 - A Forum For Payers

FC18120

REGISTRATION FEE:

	ADVANTAGE PRICING	Standard	Onsite
Health Plan Rate, Conference + Workshop	\$1299	\$1599	\$1699
Pharma/Biotech Rate, Conference + Workshop	\$2399	\$2699	\$2799
Health Plan Rate, Conference Only	\$999	\$1299	\$1399
Pharma/Biotech Rate, Conference Only	\$2099	\$2399	\$2499

Fee includes continental breakfast, lunch, wine and cheese reception, refreshments and conference documentation. Credit Card (Visa, MC, AMEX, Discover) or checks accepted. Please make checks (in U.S. funds drawn on a U.S. bank) payable to: CBI. (No personal checks accepted.) PLEASE NOTE: All advertised discounts are taken from the full, Standard Rate.

GROUP RATE:

Looking to bring your team? Contact Information Services to learn about potential group savings. Call 800-817-8601 or email cbireg@cbinet.com.

** Advantage pricing rates do apply when applicable. Offer may not be combined with any other special pricing promotions. Offer may be used at CBI co-located events.*

SATISFACTION GUARANTEED:

CBI stands behind the quality of its conferences. If you are not satisfied with the quality of the conference, a credit will be awarded towards a comparable CBI conference of your choice. Please contact 800-817-8601 for further information. Advanced preparation for CBI conferences is not required.

SUBSTITUTION AND CANCELLATION:

Your registration may be transferred to a member of your organization up to 24 hours in advance of the conference. All cancellations received in writing on or before 14 days prior to the start date of the event will be refunded, less a \$399 administrative charge. No refunds will be made after this date; however, the registration fee less the \$399 administrative charge can be credited to another CBI conference if you register within 30 days from the date of this conference to an alternative CBI conference scheduled within the next six months. In case of conference cancellation, CBI's liability is limited to refund of the conference registration fee only. Cancellation of a conference due to events beyond our control* are subject to a \$399 administrative charge should you or a colleague be unable to attend the rescheduled date. CBI reserves the right to alter this program without prior notice. Please Note: Speakers and agenda are subject to change. In the event of a speaker cancellation, every effort to find a suitable replacement will be made. The opinions of the conference faculty do not necessarily reflect those of the companies they represent or CBI.

**Events beyond our control include: severe weather conditions, natural and man-made disasters and any other similar events.*

VENUE:

Monte Carlo

3770 Las Vegas Blvd S
Las Vegas, NV 89109
Reservations: (888) 529-4828
Hotel direct line: (702) 730-7777

ACCOMMODATIONS:

To receive CBI's special discounted hotel rate online or by phone, please go to:

- **Online:** www.cbinet.com/specialtytherapies
- **Phone reservations:** (888) 529-4828 and mention CBI's Specialty Therapies

Book Now! The Monte Carlo is accepting reservations on a space and rate availability basis. Rooms are limited, so please book early. All travel arrangements subject to availability.

PLEASE NOTE: All hotel reservations for this conference should be booked directly with the hotel. CBI does not use Housing Bureaus and none are authorized to call on our behalf.



REGISTER AT WWW.CBINET.COM/SPECIALTYTHERAPIES • 800-817-8601